Form 4: Alkermes CEO Richard Pops Acquires Stock Options

Alkermes CEO Richard F. Pops was granted stock options to purchase 293,921 ordinary shares on February 19, 2025.

Summary

• Richard F. Pops, CEO and Director of Alkermes plc, was granted employee stock options on February 19, 2025.
• The options allow him to purchase 293,921 ordinary shares at an exercise price of $35.84.
• The options vest in four equal annual installments starting on February 19, 2026, and expire on February 19, 2035.
• Following the transaction, Pops directly owns options for 293,921 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management with shareholder interests.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally aligned with industry norms to promote long-term value creation.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the CEO to increase the company's value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Form 4, Richard Pops, Alkermes, CEO, equity, ownership